CD8A and neoplasm: We found that anti-NKG2A significantly reduces the exhaustion of intratumoral CD8 T cells induced by heterologous prime-boost vaccination resulting in lower frequency of PD-1+Tim-3+NKG2A+ cells, which was associated with prolonged tumor control and increased mouse survival.